3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
US biotech Insmed (Nasdaq: INSM) yesterday released positive top-line results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase III trial to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. 29 May 2024
After more than 30 years with neuroscience-focused biopharma Neurocrine Biosciences, founder and chief executive Kevin Gorman is to retire in October - albeit staying on as a board member. 29 May 2024
Russia has suspended state purchases of a number of original anti-cancer drugs due to problems associated with sanctions and the ever-growing isolation of the country in the international arena, The Pharma Letter’s local correspondent reports. 29 May 2024
The Bill & Melinda Gates Medical Research Institute (Gates MRI) has appointed Patrice Matchaba, as chief executive (CEO), starting June 10, 2024. 29 May 2024
US healthcare giant Johnson & Johnson has acquired Yellow Jersey Therapeutics (YJT), a wholly-owned subsidiary of Swiss biotech Numab Therapeutics. 29 May 2024
Cambridge, USA-based Agios Pharmaceuticals closed up more than 23% at $38.81 yesterday, after it revealed it has agreed to sell its rights to its 15% royalty on potential US net sales of Servier’s vorasidenib to Royalty Pharma. 29 May 2024
Chief Executive Officers of the world’s largest generic and biosimilar medicines companies recently met in Vienna, Austria, to provide strategic advice to the International Generic and Biosimilar Medicines Association (IGBA). 29 May 2024
Sapreme, a Dutch biotech developing next-generation RNA therapeutics for genetically-driven diseases, has appointed Marco Timmers as chief executive. 28 May 2024
The European Commission today approved, under EU State aid rules, the first Important Project of Common European Interest (IPCEI) to support research, innovation and the first industrial deployment of healthcare products, as well as innovative production processes of pharmaceuticals. 28 May 2024
Shares of Swedish biotech Calliditas Therapeutics shot up more than 78% to 202.60 kronor by late afternoon, on news of a takeover bid from Asahi Kasei. 28 May 2024
The drug shortage crisis in the USA, intensified by supply chain disruptions and increased demand, presents a significant opportunity for Indian pharmaceutical companies to offer essential support. 28 May 2024
Australia’s Neuren Pharmaceuticals has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). 28 May 2024
Privately-held Swiss drug firm Ewopharma it has entered into a strategic commercial collaboration with China’s CStone Pharmaceuticals to gain rights for sugemalimab in Switzerland and 18 Central Eastern European countries (CEE). 28 May 2024
The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Sarclisa (isatuximab) alongside bortezomib, lenalidomide and dexamethasone (VRd) for transplant-ineligible newly diagnosed multiple myeloma (NDMM). 28 May 2024
Russia has registered a new domestic drug, fluorothiazinone, which is intended for the treatment of bacterial infections caused by microorganisms resistant to antibiotics, reports The Pharma Letter’s local correspondent. 28 May 2024
USA-based Nippon Shinyaku subsidiary NS Pharma has published a disappointing initial analysis from an important trial of Viltepso (viltolarsen). 28 May 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.